Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AstraZeneca

Revenues, earnings fall off patent cliff

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 

3Q Revenues: $6.3 billion (-6%)

3Q Earnings: $1.2 billion (-27%)

YTD Revenues: $20.7 billion (-9%)

YTD Earnings: $3.1 billion (-26%)

Comments: The impact from products that recently lost exclusivity is estimated at $350 million in the quarter. U.S. revenues were down 8% with declines in Crestor (-11% to $1.4 billion) and Nexium (-5% to $918 million), partially offset by growth for Symbicort (+7% to $839 million), the diabetes franchise, FluMist (+30% to $188 million) and Brilinta/Brilique (+208% to $75 million). The negative impact of U.S healthcare reform in the quarter was approximately $199 million. Rest of World (ROW) revenue was down 2% related to the loss of exclusivity for Atacand (-35% to $143 million), Nexium, and Seroquel IR (-47% to $84 million), combined with generic competition for Seroquel XR (-10% to $339 million), partially offset by revenue increases for Brilique and the diabetes franchise.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters